Abstract
The evolving paradigm of heart failure has now been expanded to include the favorable neurohormonal, structural and hemodynamic profile of B-type natriuretic peptide [BNP]. As a marker of left ventricular dysfunction, BNP is a practical tool that facilitates diagnosis, contributes to prognostic evaluations and tracks disease severity. BNP elevations vary according to gender, disease states and perhaps obesity but in general elevated levels are consistent not only with left ventricular stress but likely represent the best surrogate for ongoing left ventricular remodeling. The full utility of BNP surveys has not yet been realized but emerging areas of use include clinical assessment by physician extenders, post-MI assessment, and a target of tailored therapy for heart failure. New biomarkers for heart failure similar to BNP are on the horizon but their clinical niche has yet to be determined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stewart S, Horowitz JD. Home-based intervention in congestive heart failure; long term implications on readmission and survival. Circulation 2002;205:2861–2866.
Adams KF, Mathur VS, Gheorghiade M. B-type natriuretic peptide: From bench to bedside.AmHeart J 2003;145:S34–S46.
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of btype natriuretic peptide in the emergency diagnosis of Practical Considerations for BNP Use 373 heart failure. New England Journal of Medicine 2002; 347:161–167.
Chen HH, Burnett JC. The natriuretic peptides in the pathophysiology of congestive heart failure. Current Cardiology Reports 2000;3:198–205.
Shapiro BP, Chen HH, Burnett JC, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clinic Proceedings 2003;78:481–486.
Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. New England Journal of Medicine 2000;343:246–253.
Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proceedings of the National Academy of Science 2000;97:4239–4244.
John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679–681.
Abraham WT, Lowes BD, Ferguson DA, et al. Systemic, hemodynamic, neurohormonal, and renal effects of a steady state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. Journal of Cardiac Failure 1998;4:37–44.
Weber KT. Aldosterone in congestive heart failure. New England Journal of Medicine 2001;345:1689–1697.
Hobbs RE, Mills RM, Young JB. An update on nesiritide for treatment of decompenasted heart failure. Expert Opinion of Investigational Drugs 2001;10:935–942.
Harrison A, et al. BNP Concentration for the prediction of clinical events. Annals of Emergency Medicine 2002;39:131–138.
DeLemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New England Journal of Medicine 2002;345:1014–1021.
Peterson LR, Schechtman KB, Ewald GA, Geltman EM, et al. The effect of beta adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. The Journal of Heart and Lung Transplantation 2003;22:70–77.
Cohn JN, Tognoni GA. A randomized trial of the antiotensin receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001;345:1667–1675.
Publication Committee for the Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heat falure: A randomized controlled trial. Journal of the American Medical Association 2002;287:1531–1540.
Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of Btype natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002;105:595–601.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, et al. Plasma brain natriuretic peptide concentration; impact of age and gender. Journal of the American College of Cardiology 2002;40:976–982.
Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic peptide concentrations in patients with endstage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clinic Proceedings 2001;76:1111–1119.
Personal communicationi: M. Mehra.
Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-Terminal pro-B-type natriuretic peptide and long term mortality in acute coronary syndromes. Circulation 2002;106:2913–2918.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (n-BNP) concentrations. Lancet 2000;355:1126–1130.
Loudonpaa M, Vuolteenaho O, Eskelinen S, Rushoaho H. Effects of adrenomedullin on hypertrophic responses induced by angiotension II, endothelin-1 and phenylephrine. Peptides 2001;22:1859–1866.
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker. Circulation 2003;107:721–726.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yancy, C.W. Practical Considerations for BNP Use. Heart Fail Rev 8, 369–373 (2003). https://doi.org/10.1023/A:1026107701983
Issue Date:
DOI: https://doi.org/10.1023/A:1026107701983